Shalby growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+5.0%+12.3%
EBITDA+7.7%+1.4%
Net Income+1,710.2%−20.0%
EPS (adj.)+501.6%−18.0%
Total Assets+8.0%+12.8%
Total Equity+1.0%+2.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SHALBY₹121.96

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,311 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+5.0+12.3
EBITDA+7.7+1.4
Net Income+1710.2-20.0
EPS (adj.)+501.6-18.0
Total Assets+8.0+12.8
Total Equity+1.0+2.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.